Elicio announces preliminary analysis from Phase 2 AMPLIFY-7P trial

Elicio Therapeutics (ELTX) announced that preliminary analysis of patients in the ongoing Phase 2 AMPLIFY-7P trial indicated that specific Human Leukocyte Antigen types were not associated with a patient’s ability to elicit robust mKRAS-specific T-cell response following treatment with ELI-002 7P. Among 89 patients treated with ELI-002 7P, a total of 1,132 unique HLAs were represented across the primary class I and class II variants, highlighting substantial genetic diversity within the study population. These findings are consistent with a growing body of evidence indicating that mKRAS antigens can be presented across a broad range of HLA types. Elicio’s data is consistent with recent analysis published in Cell Reports Methods that found T cells specific to mKRAS G12D and/or G12V in 20/20 healthy donors evaluated across a diverse HLA background, suggesting that the majority of patients possess mKRAS-presenting HLAs and include mKRAS-specific T cell responses within their immune repertoire.